icon-folder.gif   Conference Reports for NATAP  
 
  EASL 47th Annual Meeting
April 18th - 22nd 2012
Barcelona, Spain
Back grey_arrow_rt.gif
 
 
 
Safety and Antiviral Activity of ABT-267, a Novel NS5A Inhibitor, During 3-Day Monotherapy: First Study in HCV Genotype-1 (GT1)-Infected Treatment-Naïve Subjects
 
 
  Reported by Jules Levin
EASL 2012 Apr 18-22 Barcelona Spain
 
Eric Lawitz1, Thomas Marbury2, Andrew Campbell3, Emily Dumas3, Tami Pilot-Matias3, Preethi Krishnan3, Carolyn Setze3, Wangang Xie3, Thomas Podsadecki3, Barry Bernstein3, Laura Williams3 1Alamo Medical Research, San Antonio, Texas, United States; 2Orlando Clinical Research Center, Orlando, Florida, United States; 3Abbott, Abbott Park, Illinois, United States

EASL1.gif

EASL2.gif

EASL3.gif

EASL4.gif

EASL5.gif

EASL6.gif

EASL7.gif

EASL8.gif

EASL9.gif